TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07325214: Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

Sponsor: IMGT Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 360 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07325214 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07325214 Rescue Dossier →